【摘要】 目的 分析评估不同剂量聚乙二醇重组人生长激素对治疗特发性矮小症患儿胰岛素样生长因子-1水平的影响。方法 随机选取2020年6月至2023年6月福建医科大学附属第二医院收治的80例特发性矮小症患儿进行回顾性分析，将其按照使用聚乙二醇重组人生长激素的不同剂量分为对照组和观察组，每组各40例。其中，对照组的40例特发性矮小症患儿采取小剂量进行治疗，观察组的40例特发性矮小症患儿则采取0.2 U/(kg·d)进行治疗。比较评估两组患者的临床治疗效果、血糖控制情况、血清IGF-1、IGFBP-3水平、生长情况相关指标、骨代谢相关指标以及不良反应发生情况。结果 观察组空腹血糖、餐后2 h血糖低于对照组（P <0.05）；观察组血清IGF-1、血清IGFBP-3高于对照组（P <0.05）；观察组生长速度、骨龄、身高标准差高于对照组（P <0.05）；观察组碱性磷酸酶、血清钙、血清磷指标高于对照组（P <0.05）；在不良反应发生情况方面，观察组与对照组之间的数据比较无明显差异（P> 0.05）。结论 0.2 U/（kg·d）聚乙二醇重组人生长激素在促进特发性矮小症患儿的成长、骨骼功能水平提升以及血清IGF-1和IGFBP-3水平的改善方面均具有比小剂量药物治疗更加显著的治疗效果，并且无额外的不良反应，安全可靠。更多还原

【Abstract】 Objective Analyze and evaluate the effect of different doses of polyethylene glycol recombinant human growth hormone on the level of insulin-like growth factor-1 in the treatment of children with idiopathic dwarfism. Methods A total of 80 children with idiopathic nanosomia admitted to the Second Affiliated Hospital of Fujian Medical University from June 2020 to June 2023 were randomly selected for retrospective analysis, and divided into control group and observation group according to different doses of polyethylene glycol recombinant human growth hormone, with 40 cases in each group. Among them, 40 children with idiopathic nanosomia in the control group were treated with low dose, and 40 children with idiopathic nanosomia in the observation group were treated with0.2 U/(kg·d). Comparing the clinical therapeutic effect, blood glucose control, serum IGF-1, IGFBP-3 levels, growth-related indexes, bone metabolism related indexes and the occurrence of adverse reactions.Results Fasting blood glucose and 2 hours postprandial blood glucose in observation group were lower than those in control group(P<0.05);Serum IGF-1 and IGFBP-3 in observation group were higher than those in control group(P<0.05). The standard deviation of growth rate, bone age and height in observation group were higher than those in control group(P<0.05). The indexes of alkaline phosphatase, serum calcium and serum phosphorus in observation group were higher than those in control group(P<0.05). There was no significant difference in the occurrence of adverse reactions between the observation group and the control group(P<0.05). Conclusions 0.2 U/(kg·d) polyethylene glycol recombinant human growth hormone has a more significant therapeutic effect than low-dose drug therapy in promoting the growth of children with idiopathic nanosomia, improving the level of bone function and improving the level of serum IGF-1 and IGFBP-3, and has no additional adverse reactions, and is safe and reliable.更多还原